Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 12—December 2004

Dispatch

Protective Effectiveness of Hantavirus Vaccine

Keeho Park*Comments to Author , Chang Soo Kim†, and Ki-Tae Moon‡
Author affiliations: *National Cancer Center, Goyang, Republic of Korea; †Republic of Korea Army, Gyeryong, Republic of Korea; ‡Yonsei University College of Medicine, Seoul, Republic of Korea

Main Article

Table

Characteristics of patients and matched controlsa

Characteristic No. doses (matched sets)
3 (31)
2 (38)
1 (41)
Patients Controls Patients Controls Patients Controls
Median age (y) 
(mean ± SD) 22.0 
(23.2 ± 3.5) 22.0 
(22.0 ± 3.6) 22.0 
(23.2 ± 3.1) 21.0 
(22.0 ± 2.1) 22.0 
(23.4 ± 3.8) 21.0 
(22.2 ± 0.7)
% vaccinated 6.5 32.3 23.7 39.5 29.3 36.6

aAll participants were men.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO